Skip to main content
    R

    ReWalk Robotics Ltd (LFWD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $6.10
    -0.12 (-1.93%)

    Market Cap: $17.62M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(15/39)
    Avg Surprise
    -523.15%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.04
    Range$-1.04 - $-1.04
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.94-10.6%
    60d ago$-0.94-10.6%
    30d ago$-0.94-10.6%
    7d ago$-0.94-10.6%
    Current$-1.04
    Revenue Consensus
    $7M
    Range$6M - $8M
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-2.36
    Range$-2.36 - $-2.36
    1 analysts
    Revenue Consensus
    $6M
    Range$3M - $8M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.36---
    Sep 26EST
    		-$-1.04---
    Jun 26
    Reported Aug 14
    		$-1.46$-1.49+2.01%Beat+60.8%
    Mar 26
    Reported May 15
    		$-6.70$-0.34-1870.59%Miss-1356.5%
    Dec 25
    Reported Mar 18
    		$-2.85$-1.08-163.89%Miss-650.0%
    Sep 25
    Reported Nov 14
    		$-2.28$-1.92-18.75%Miss+45.7%
    Jun 25
    Reported Aug 14
    		$-3.72$-2.88-29.17%Miss+38.0%
    Mar 25
    Reported May 15
    		$-0.46$-0.33-39.39%Miss+93.8%
    Dec 24
    Reported Mar 7
    		$-0.38$-0.33-15.15%Miss+91.0%
    Sep 24
    Reported Nov 12
    		$-4.20$-3.78-11.11%Miss+37.5%
    Jun 24
    Reported Aug 14
    		$-6.00$-6.60+9.09%Beat-13.4%
    Mar 24
    Reported May 15
    		$-7.44$-8.40+11.43%Beat-31.2%
    Dec 23
    Reported Feb 27
    		$-4.20N/A+54.55%Beat+44.4%
    Sep 23
    Reported Nov 14
    		$-6.72$-8.40+20.00%Beat+11.1%
    Jun 23
    Reported Aug 11
    		$-5.29$-5.88+10.03%Beat+10.0%
    Mar 23
    Reported May 11
    		$-5.67$-6.72+15.63%Beat-1.8%
    Dec 22
    Reported Feb 23
    		$-7.56$-5.88-28.57%Miss-50.0%
    Sep 22
    Reported Nov 7
    		$-7.56$-5.04-50.00%Miss-50.0%
    Jun 22
    Reported Aug 9
    		$-5.88$-3.36-75.00%Miss+0.0%
    Mar 22
    Reported May 13
    		$-5.57$-4.20-32.62%Miss+15.0%
    Dec 21
    Reported Feb 24
    		$-5.04$-3.36-50.00%Miss+57.1%
    Sep 21
    Reported Nov 10
    		$-5.04$-5.04+0.00%Beat+66.7%
    Jun 21
    Reported Aug 9
    		$-5.88$-5.04-16.67%Miss+68.2%
    Mar 21
    Reported May 11
    		$-6.55$-5.88-11.39%Miss-152.9%
    Dec 20
    Reported Feb 18
    		$-11.76$-11.76+0.00%Beat+71.4%
    Sep 20
    Reported Nov 10
    		$-15.12$-13.44-12.50%Miss+60.9%
    Jun 20
    Reported Aug 12
    		$-18.48$-22.68+18.52%Beat+75.0%
    Mar 20
    Reported May 28
    		$-2.59$-0.26-896.15%Miss+97.5%
    Dec 19
    Reported Feb 20
    		$-41.16$-30.24-36.11%Miss+80.4%
    Sep 19
    Reported Nov 13
    		$-38.64$-37.80-2.22%Miss+85.8%
    Jun 19
    Reported Aug 8
    		$-73.92$-41.16-79.59%Miss+80.4%
    Mar 19
    Reported May 7
    		$-105.00$-84.00-25.00%Miss-185.7%
    Dec 18
    Reported Feb 8
    		$-210.00$-294.00+28.57%Beat+50.3%
    Sep 18
    Reported Nov 8
    		$-273.00$-294.00+7.14%Beat+40.9%
    Jun 18
    Reported Aug 14
    		$-378.00$-336.00-12.50%Miss+37.2%
    Mar 18
    Reported May 10
    		$-36.75$-0.22-16604.55%Miss+46.2%
    Dec 17
    Reported Mar 8
    		$-422.73$-546.00+22.58%Beat+57.6%
    Sep 17
    Reported Nov 2
    		$-462.21$-735.00+37.11%Beat-
    Jun 17
    Reported Aug 3
    		$-602.39$-805.00+25.17%Beat-
    Mar 17
    Reported May 4
    		$-68.25$-10.08-577.08%Miss-
    Dec 16
    Reported Feb 17
    		$-997.29$-934.50-6.72%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.46EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-141.30%Operating Margin-62.70%
    ROE-225.60%ROIC-183.23%
    Financial Health
    Debt/Equity0.36xInterest CoverageN/A
    Current Ratio2.33xQuick Ratio1.77x
    Trading Statistics
    Beta0.48Avg Volume5.78K
    52-Week High$9.6152-Week Low$4.14

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.32
    SMA 20$6.63
    SMA 50$7.07
    SMA 200$7.07
    EMA 10$6.40
    EMA 20$6.59
    EMA 50$6.91
    EMA 200$7.50

    MACD

    Line: -0.25Signal: -0.22Hist: -0.03

    ADX

    ADX: 23.9+DI: 12.8-DI: 26.9

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down68.0
    PSAR$6.61

    Bollinger Bands

    Upper Band$7.39
    Lower Band$5.88
    %B Position2283%(Upper)
    Band Width0.15

    RSI (14-Day)

    Neutral
    37.3

    Momentum Oscillators

    Stoch %K55.6
    Stoch %D60.2
    Williams %R-52.4
    ROC (10d)-11.7%
    Momentum-0.81
    CCI (20d)-102.2
    MFI (14d)34.8

    Volatility Measures

    ATR (14d)$0.38(6.3%)
    StdDev (20d)0.38
    Hist Vol70.1%(High)

    Volume Flow

    VWAP$6.11
    OBV-760.1K
    AD Line24.0B
    CMF (20d)-0.153

    Volume Metrics

    Avg Vol (20d)5.5K
    Vol Ratio1.9x(High)
    VWMA (20d)$6.54

    Pivot Points

    R3$6.62
    R2$6.54
    R1$6.38
    Pivot Point$6.30
    S1$6.14
    S2$6.06
    S3$5.90

    Advanced Oscillators

    TSI-20.98
    Ultimate Osc60.2
    KST-116.23

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$6.62M$3.92M$5.08M$6.20M$5.72M$5.03M$7.54M$6.13M$6.71M$5.28M$6.88M$4.40M
    Cost of Revenue$3.91M$2.58M$3.99M$3.49M$3.21M$2.91M$5.70M$3.91M$3.95M$3.89M$4.44M$3.54M
    Gross Profit$2.71M$1.34M$1.09M$2.71M$2.51M$2.12M$1.84M$2.22M$2.76M$1.40M$2.44M$863,000
    Operating Expenses$6.86M$11.68M$6.21M$5.85M$9.07M$6.97M$17.07M$5.39M$7.20M$7.90M$8.58M$8.80M
    R&D$1.75M$5.84M$843,000$721,000$767,000$918,000$1.13M$998,000$1.21M$1.29M$1.32M$1.26M
    SG&A$1.58M$2.56M$2.28M$1.96M$1.74M$2.22M$1.77M$240,000$1.59M$1.59M$2.42M$3.46M
    Operating Income$-4,152,000$-10,339,000$-5,118,000$-3,140,000$-6,563,000$-4,853,000$-15,228,000$-3,174,000$-4,443,000$-6,502,000$-6,137,000$-7,942,000
    Interest Income$0$0$0$-23,000$0$0$0$0$0$0$0$0
    Interest Expense$7.36M$448,000$303,000$23,000$0$0$47,000$0$0$0$0$0
    Income Before Tax$-11,509,000$-10,787,000$-5,421,000$-3,163,000$-6,562,000$-4,823,000$-15,275,000$-3,055,000$-4,299,000$-6,270,000$-5,717,000$-7,531,000
    Income Tax Expense$10,000$6,000$-73,000$7,000$0$11,000$3,000$29,000$5,000$6,000$-78,000$0
    Net Income$-11,519,000$-10,793,000$-5,348,000$-3,170,000$-6,562,000$-4,834,000$-15,278,000$-3,084,000$-4,304,000$-6,276,000$-5,639,000$-7,531,000
    EBITDA$-10,996,000$-4,841,000$-5,046,000$-3,057,000$-6,474,000$-4,763,000$-14,309,000$-2,089,000$-3,346,000$-5,314,000$-5,188,000$-6,700,000
    EBIT$-11,509,000$-10,787,000$-5,118,000$-3,140,000$-6,562,000$-4,853,000$-15,275,000$-3,055,000$-4,299,000$-6,270,000$-6,137,000$-7,531,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about LFWD

    News

    Lifeward (LFWD) Publishes Long-Term Safety Study on ReWalk Exoskeleton for Paraplegia Users

    Lifeward Ltd (LFWD) announced positive results from a long-term safety study on its ReWalk Personal Exoskeleton for paraplegia patients...

    GuruFocus•10/14/26•Neutral

    Lifeward’s ReWalk® Personal Exoskeleton Demonstrates

    Lifeward Ltd. announced that an independent peer-reviewed study confirmed the long-term safety, sustained use, and high patient satisfaction with its ReWalk® Personal Exoskeleton for individuals with chronic paraplegia....

    GlobeNewswire•10/14/26•Neutral

    Study on Lifeward's ReWalk exoskeleton shows long-term home use

    A new independent peer-reviewed study published in "Spinal Cord Series and Cases" evaluated the long-term home use of Lifeward Ltd.'s ReWalk Personal Exoskeleton for individuals with chronic paraplegia. The study...

    StreetInsider•10/14/26•Bullish

    Seven people with paralysis used a walking aid at home for years. No falls or device-related fractures were reported.

    A new independent peer-reviewed study published by Lifeward (LFWD) highlights the long-term safety, utilization...

    Stock Titan•10/14/26•Bullish

    Study shows ReWalk exoskeleton maintains long-term home use

    Lifeward Ltd. announced the publication of a peer-reviewed study demonstrating the long-term effectiveness of its ReWalk Personal Exoskeleton for individuals with chronic paraplegia. The study...

    Investing.com•10/14/26•Bullish

    LFWD Valuation and Fair Value

    P/E
    -0.5x
    P/B
    1.4x
    See GNG's fair value

    LFWD Profitability: Margins, ROIC and FCF

    Gross margin
    36.0%
    Operating margin
    -62.7%
    Net margin
    -141.3%
    ROIC
    -183.2%
    ROE
    -225.6%
    FCF margin
    -78.3%

    LFWD Competitors

    CompanyTicker
    Retractable Technologies IncRVP
    Neuphoria Therapeutics IncNEUP
    Sensei Biotherapeutics IncSNSE
    Quantum BioPharma Ltd.QNTM
    Akari Therapeutics PLCAKTX
    Jasper Therapeutics IncJSPR
    Modular Medical IncMODD
    Dyadic International IncDYAI

    Sector: Healthcare

    LFWD Bull Case vs Bear Case

    Bull case

    • LFWD grew quarterly revenue 15.7% year over year.

    Bear case

    • LFWD has a -141.3% net profit margin.
    • LFWD beat EPS estimates in 12.5% of its last 8 reported quarters.

    LFWD Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -268.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.04
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About LFWD

    Does LFWD pay dividends?

    ReWalk Robotics Ltd (LFWD) does not currently pay a regular dividend.

    What is LFWD's market cap?

    ReWalk Robotics Ltd (LFWD) has a market capitalization of $17.62M with a current stock price of $6.10.

    Related stocks

    Sector: Healthcare

    All stocks starting with L

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In